AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 4 - (NewsRx.com & NewsRx.net) -- Chlorogen, Inc., has signed a joint development and supply agreement with Sigma-Aldrich Fine Chemicals, a division of Sigma-Aldrich Corp. (SIAL), which is expected to produce the first commercial products from chloroplast transformation technology (CTT).
Sigma-Aldrich will fund an undisclosed portion of Chlorogen's efforts to produce four specific proteins in tobacco plants. The proteins will be sold to the reagent and cell culture markets and have pre-identified applications as active pharmaceutical ingredients.
Chloroplast transformation technology is a new way of introducing genes into plants to produce beneficial proteins. Pharmaceutical proteins produced in plant cells provide safety and cost advantages over those produced from animal-derived cells, according to the company. CTT is expected to revolutionize plant-derived protein production by greatly increasing the protein output of plants and significantly lowering the cost of pharmaceutical production.
The current method of producing proteins in plants involves introducing a new gene into the cell nucleus. CTT, in contrast, introduces a new gene into the approximately 100 chloroplasts within a plant cell. Each chloroplast contains about 100 copies of the plant's genetic structure.
Therefore, chloroplast transformation can produce ...
Source: HighBeam Research, Agreement inked to produce first-ever products from chloroplasts.